MNPR Monopar Therapeutics
- Stocks
- Healthcare
- NASDAQ: MNPR
Price (delayed)
$82.5
Market cap
$509.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.85
Enterprise value
$469.6M
Relative Growth:
Rel. Growth:
4
Relative Strength:
Rel. Strength:
97
Relative Valuation:
Rel. Valuation:
N/A
Relative Profitability:
Rel. Profitability:
1
Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of
Highlights
The EPS has plunged by 67% YoY but it has grown by 3.5% from the previous quarter
The net income has dropped by 143% year-on-year and by 4.5% since the previous quarter
Monopar Therapeutics's quick ratio has decreased by 8% from the previous quarter
Key stats
What are the main financial stats of MNPR
Market
Valuations
Earnings
Shares outstanding
6.17M
Market cap
$509.02M
Enterprise value
$469.6M
Price to earnings (P/E)
N/A
Price to book (P/B)
9.66
Price to sales (P/S)
N/A
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$19.11M
Net income
-$17.31M
EBIT
-$17.31M
EBITDA
-$17.31M
Free cash flow
-$9.81M
Per share
Balance sheet
Liquidity
EPS
-$3.85
EPS diluted
-$3.85
Free cash flow per share
-$1.4
Book value per share
$8.54
Revenue per share
$0
TBVPS
$7.7
Total assets
$53.87M
Total liabilities
$1.66M
Debt
$80,366
Equity
$52.2M
Working capital
$52.16M
Debt to equity
0
Current ratio
33.94
Quick ratio
33.63
Net debt/EBITDA
2.28
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-39.5%
Return on equity
-41.8%
Return on invested capital
-198.4%
Return on capital employed
-33.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MNPR stock price
How has the Monopar Therapeutics stock price performed over time
Intraday
-0.25%
1 week
-1.97%
1 month
-16.99%
1 year
423.81%
YTD
275%
QTD
1.02%
Financial performance
How have Monopar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.11M
Net income
-$17.31M
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 155% YoY and by 8% from the previous quarter
The net income has dropped by 143% year-on-year and by 4.5% since the previous quarter
Price vs fundamentals
How does MNPR's price correlate with its fundamentals
Growth
What is Monopar Therapeutics's growth rate over time
Valuation
What is Monopar Therapeutics stock price valuation
P/E
N/A
P/B
9.66
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 67% YoY but it has grown by 3.5% from the previous quarter
MNPR's price to book (P/B) is 154% more than its last 4 quarters average of 3.8
The equity has contracted by 2.6% from the previous quarter
Efficiency
How efficient is Monopar Therapeutics business performance
MNPR's return on equity has surged by 62% year-on-year and by 25% since the previous quarter
The return on assets has surged by 56% year-on-year and by 23% since the previous quarter
Monopar Therapeutics's ROIC has increased by 34% from the previous quarter
Dividends
What is MNPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MNPR.
Financial health
How did Monopar Therapeutics financials performed over time
The total liabilities has soared by 53% year-on-year and by 12% since the previous quarter
Monopar Therapeutics's quick ratio has decreased by 8% from the previous quarter
The company's debt is 100% lower than its equity
The equity has contracted by 2.6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.